Calico (company)

Calico Appoints Michael Lenardo, M.D., as Chief Scientific Officer

Retrieved on: 
Thursday, March 28, 2024
Internal medicine, University, Natural science, Biomedicine, Alphabet, Calico (company), Immune system, SAN, Research, Science, Whitehead Institute, National academy, Biology, Biochemistry, Johns Hopkins University, NIAID, Most, Nobel, Bangladesh Technical Education Board, Birth, Biomedical Research, O.B.E, Infection, Ageing, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 28, 2024 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and age-related diseases, and founded by Alphabet and Arthur D. Levinson, Ph.D., today announced the appointment of Michael Lenardo, M.D., as its new Chief Scientific Officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 28, 2024 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and age-related diseases, and founded by Alphabet and Arthur D. Levinson, Ph.D., today announced the appointment of Michael Lenardo, M.D., as its new Chief Scientific Officer.
  • Dr. Lenardo is an accomplished molecular immunologist and geneticist whose medical research career spans four decades.
  • "Securing someone of Mike's caliber for the critical role of Chief Scientific Officer is a major achievement for Calico," said Dr. Levinson, CEO of Calico.
  • "The commitment to scientific excellence and integrity at Calico, coupled with the highly talented team, is truly impressive and reflected in the impactful progress they are making.

Physics-Powered GenAI Biotech Gero Raises $6M to Find Root Causes of Aging and Age-Related Diseases

Retrieved on: 
Wednesday, October 18, 2023
Biotechnology, Technology, Health, General Health, Pharmaceutical, Other Science, Research, Infectious Diseases, Artificial Intelligence, Genetics, Science, Longevity, Ageing, Notifiable disease, NYSE, Therapy, Calico (company), Hope, Human, Conditional sentence, BioRxiv, LLM, Phenotype, Investment, Popular Mechanics, Mouse, Quality of life, Pfizer, LHM, Nature Communications, Altos Labs, Biology, Mechanics, American Association for the Advancement of Science, VC, Herbert Wertheim School of Public Health and Human Longevity Science, Pharmaceutical industry, Medical device, Dietary supplement, Amazon

Gero , a biotechnology company focused on aging and chronic diseases, has closed $6M in a Series A extension round.

Key Points: 
  • Gero , a biotechnology company focused on aging and chronic diseases, has closed $6M in a Series A extension round.
  • By applying cutting-edge generative AI tools to analyze real-world longitudinal human health data, Gero is dedicated to finding novel cures for age-related diseases.
  • Its goal is to unravel the mysteries behind human aging and halt the aging process.
  • Gero’s approach allows separating the effects of aging from the effects of diseases enabling human genetics-driven target discovery for chronic and age-related diseases.

Announcing the Digital In Vivo Alliance (DIVA), a precompetitive consortium to develop, validate and promote the use of AI-enabled digital biomarkers in preclinical in vivo research.

Retrieved on: 
Thursday, October 19, 2023
Digital, Biomarker, DVM, Calico (company), Respiratory disease, Doctor of Philosophy, Research, Multimedia, Public sector, BioMarin Pharmaceutical, Novartis, Machine learning, DIVA, Algorithm, AbbVie, Jackson Laboratory, AI, Epilepsy, Patient, Dermatitis, SAN, Medical imaging, Vaccine

DIVA has the mission to collaboratively advance digital biomarkers for preclinical in vivo research through their development, validation, adoption, and regulatory acceptance.

Key Points: 
  • DIVA has the mission to collaboratively advance digital biomarkers for preclinical in vivo research through their development, validation, adoption, and regulatory acceptance.
  • Digital In Vivo Alliance members work together non-competitively, for the purpose of exploring preclinical applications of AI-enabled digital biomarkers from home cage-compatible technologies.
  • This collaborative approach serves to accelerate the understanding and integration of digital biomarkers in preclinical models, fortifying our shared vision of enabling novel therapies through the adoption of digital biomarkers in AI-enhanced in vivo research.
  • Inquiries about DIVA and the discovery, development, and adoption of digital biomarkers can be directed to the Digital In Vivo Alliance using the contact information below or at DIVA.bio .

Terray Therapeutics and Calico Enter into a Multi-Target Collaboration to Discover Small Molecule Therapeutics for Age-Related Diseases

Retrieved on: 
Wednesday, October 12, 2022
Therapy, Machine learning, Patient, Biotechnology, Biology, Research, Multimedia, Alphabet, Cancer, Automation, Drug discovery, AI, Degenerative disease, Calico (company), Nanotechnology, Ageing, Pharmaceutical industry, Textile printing, Calico, Lionel Terray, Chemical substance

PASADENA, Calif. and SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 /PRNewswire/ -- Terray Therapeutics, a biotechnology company accelerating drug discovery through the application of computational approaches to precisely generated chemical data at scale; and Calico Life Sciences, a biotechnology organization focused on age-related interventions and founded by Alphabet and Arthur D. Levinson, today announced a research collaboration to discover and develop small molecule therapeutics for diseases of aging, including cancer. 

Key Points: 
  • Under the terms of the agreement, Terray and Calico will identify small molecule leads against a set of targets nominated by Calico using the Terray tNova platform, with Calico subsequently assuming responsibility for development and commercialization.
  • Terray will receive an upfront payment and is eligible to receive milestones as well as tiered royalties on net sales.
  • "Our combined expertise will leverage the scale, precision, and speed of our tNova platform to rapidly discover and advance therapeutics for patients."
  • "We look forward to partnering with the team at Terray to jointly discover first-in-class therapeutics against age-related diseases."

DTx Pharma Appoints Peter Condon as Chief Business Officer

Retrieved on: 
Tuesday, June 28, 2022
Health, Genetics, Other Science, Clinical Trials, Research, Science, Biotechnology, Wharton School of the University of Pennsylvania, Patient, Business, LinkedIn, Heart, Biotechnology, Liver, Research, Single-frequency network, National Institute, Tissue, Foundation for the National Institutes of Health, Degenerative disease, Pharma, Retina, Harvard University, Company, Disease, Goal, Eli Lilly and Company, Genentech, Alexion Pharmaceuticals, Inflammation, Organic acid, NIH, MBA, Therapy, BA, RNA, Neuron, Entrepreneurship, FALCON, Lists of diseases, Twitter, Oligonucleotide, RA, Multimedia, Calico (company), Fine chemical, Management

DTx Pharma, Inc. (DTx), a privately-held biotechnology company developing novel RNA-based therapeutics to treat the genetic drivers of disease, today announced the appointment of Peter Condon as Chief Business Officer.

Key Points: 
  • DTx Pharma, Inc. (DTx), a privately-held biotechnology company developing novel RNA-based therapeutics to treat the genetic drivers of disease, today announced the appointment of Peter Condon as Chief Business Officer.
  • We are delighted to have him joining the team and look forward to working together, said Arthur T. Suckow, Co-Founder and Chief Executive Officer of DTx Pharma.
  • Mr. Condon joins DTx Pharma with more than 20 years of experience in business development, commercial planning, and operations.
  • To learn more about DTx Pharma, please visit www.dtxpharma.com and follow DTx on LinkedIn and Twitter @DTxPharma.

Embark Welcomes New Scientific Advisory Board in Lead-Up to 2022 Canine Health Summit

Retrieved on: 
Thursday, April 21, 2022
Distinguishing, CEO, Ageing, Cornell University College of Veterinary Medicine, Veterinarian, Laboratory, DNA, University of California, Berkeley, Dog, DVM, Coronavirus Scientific Advisory Board (Turkey), Research, Life, Science, Idexx Laboratories, Learning, Howard Hughes Medical Institute, Doctor of Philosophy, Population, Cornell University, Development, Technology, Love, Private practice, Veterinary medicine, UC, MacArthur Fellows Program, Myriad Genetics, Canine cancer detection, Multimedia, MS, Health, Calico (company), Forbes, Longevity, Vaccine, Management, Embark, Genomics, Genetics

BOSTON, April 21, 2022 /PRNewswire/ -- Embark Veterinary, Inc., the global leader in dog genetics, today announced its new Scientific Advisory Board in the lead-up to its second annual Canine Health Summit. The new members of the board include some of the most renowned members of the scientific community. They include three former biotech chief executives, two MacArthur Genius Prize winners, and offer a variety of expertise across veterinary pathology, genomics, epigenetics, and molecular diagnostic medicine.

Key Points: 
  • BOSTON, April 21, 2022 /PRNewswire/ -- Embark Veterinary, Inc. , the global leader in dog genetics, today announced its new Scientific Advisory Board in the lead-up to its second annual Canine Health Summit.
  • The new members of the board include some of the most renowned members of the scientific community.
  • It also illustrates the faith among human genetics experts in the power of canine genetic health discoveries potentially fueling human health discoveries in the future.
  • Embark welcomes its new Scientific Advisory Board members just as the second annual Canine Health Summit gets underway.

Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases

Retrieved on: 
Tuesday, September 14, 2021
Â, Alpha-synuclein, PD, Gaucher's disease, Patient, Gene, Eli Lilly, Rheumatoid arthritis, Department, Lists of diseases, Amyotrophic lateral sclerosis, Neurology, GD, Neurodegeneration, Genetics, University of Texas Southwestern Medical Center, GBA, Therapy, GLOBE, ALS, Diagnosis, AD, Cell, Neuron, Protein, Research, Series, Lymphatic system, Hope, Drug discovery, AbbVie, Calico (company), University, Drug development, Technology, Doctor of Philosophy, Company, Risk, Hepatitis C, Disease, Array BioPharma, GBA1, Pharmaceutical industry, Fine chemical

CHICAGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Vanqua Bio, a Chicago-based biopharmaceutical company dedicated to discovering and developing next-generation medicines for neurodegenerative diseases, today announced that it closed an $85 million Series B financing round, led by Omega Funds. The syndicate includes Series A investor OrbiMed and new investors Omega Funds, Surveyor Capital (a Citadel company), Avoro Ventures, Casdin Capital, Pontifax, Eli Lilly and Company, Logos Capital, and Osage University Partners. Proceeds from the financing will be used to accelerate the development of the company’s innovative therapeutic programs. The need for effective neurodegenerative therapies is urgent; every day, the lives of thousands of people are changed forever following a diagnosis of Parkinson’s disease (PD), Gaucher disease (GD), Alzheimer’s disease (AD), or amyotrophic lateral sclerosis (ALS).

Key Points: 
  • CHICAGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Vanqua Bio, a Chicago-based biopharmaceutical company dedicated to discovering and developing next-generation medicines for neurodegenerative diseases, today announced that it closed an $85 million Series B financing round, led by Omega Funds.
  • Vanqua Bio is helping usher in a new era of hope for people living with neurodegenerative disorders.
  • Vanqua Bios Series B financing will advance the companys best-in-class GCase activators into human testing within the next two years, initially focusing on GD and GBA-PD.
  • Co-Founder Dr. Dimitri Krainc , a leading expert on uncovering molecular pathways that contribute to neurodegenerative diseases, chairs Vanqua Bios Scientific Advisory Board.